TECHNOLOGY & DATA MANAGEMENT
of information and literature. But designing new drugs is a really complex endeavour. AI agents can help in some tasks but are not the only tool.
AI is speeding up the drug development
process by simplifying some steps to allow better choices. But it’s not a one-size-fits-all solution.
RB: Where do you see regulation with AI heading, and will it facilitate or hamper its long-term use in healthcare?
DR: At NVIDIA, we pay very careful attention to this particular topic. We think it’s a healthy debate to have within the society. People do wonder, what is going on with a particular technology. And it’s part of the process to demystify it. The progress made by these AI agents is quite surprising and it’s normal that people who are not close to the subject – which is in a way, the vast majority of us – wonder about the consequences. The debate around the regulation of AI is helping to demystify the topics. A regulation coming into place is the conclusion of reflection from the society, and that is a very healthy thing. It will help the adoption of AI, and help guide us in the right direction. And this happens whether a company likes it or not. We need this reflection to be able to progress in our research to create the best algorithm for the job.
RB: A recent survey showed that the majority of US employees have concerns about AI. How close is healthcare, at the level of medical staff, to accepting AI?
DR: We spend quite a lot of energy in this space [demystification]. There are already quite a few companies developing tools to simplify the workload and reduce the burden on the medical staff. One example is Hippocratic AI – a company we highlighted at our last GTC conference. Hippocratic AI is a virtual interface, powered by a large language model, which helps patients to adhere to their therapeutic regimen. Not only does it alleviate the burden of needing medical staff to do that, but it also helps people to be treated at home. Virtual assistants are not a new concept, but finally, we are beginning to see them being
David Ruau, EMEA business development lead for healthcare and life sciences at NVIDIA
implemented in real life; for example, in AI applications for taking medical notes and saving time for doctors, and it can go even further nowadays. We also see some innovation along those lines with AI agents that are used as ‘copilots’ for a medical doctor, the latter still being the one in charge.
RB: How will AI in healthcare look in 2050?
DR: Nobody can predict anything with certainty, but I think AI will be in every application we use. It will be the new type of ‘transaction’. Jensen Huang [NVIDIA’s CEO] described this concept in his keynote this year at GTC. It is a new commodity. AI engines are basically producing tokens, interpreting what you say, and answering questions. It can be applied to many domains of data coming in and information coming out, and that’s basically what we describe as AI factories. Research is progressing, and the future is looking very bright for this technology in healthcare. It will be pervasive, both in the daily lives of patients and in new drug research such as NVIDIA’s BioNeMo [a generative AI platform for drug discovery]. It comes back to what I said at the start, AI expands our available toolbox. The future will be based on the present, and
the present is going in this particular direction at the moment. [AI factories] are powering all the tools that we use every day. It’s a new ‘iPhone’ moment for AI, and it’s not only benefiting NVIDIA.
Outsourcing in Clinical Trials Handbook | 33
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
